English | Español

Pharmaceuticals

+ Pharmaceuticals
Patient Daily | Mar 4, 2026

CDC’s principal deputy director Ralph Abraham resigns amid leadership changes
+ Pharmaceuticals
Patient Daily | Mar 4, 2026

Merck restructures human health division ahead of Keytruda patent expiration
+ Pharmaceuticals
Patient Daily | Mar 4, 2026

Vanda receives FDA approval for new antipsychotic after previous setback
+ Pharmaceuticals
Patient Daily | Mar 4, 2026

FDA proposes regulatory path for individualized gene editing therapies targeting rare diseases
+ Pharmaceuticals
Patient Daily | Mar 4, 2026

Congress approves record $315 million for ALS research amid new treatment efforts
+ Pharmaceuticals
Patient Daily | Mar 4, 2026

Appellate court rules for REGENXBIO over Sarepta in gene therapy patent case
+ Pharmaceuticals
Patient Daily | Mar 4, 2026

Novo Nordisk’s obesity drug fails key test against Eli Lilly rival
+ Pharmaceuticals
Patient Daily | Mar 4, 2026

Gilead announces plan to acquire Arcellx for $7.8 billion ahead of FDA decision

Trending
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Regulatory
M. Y. Bailey | Aug 7, 2026

PhRMA's Zirkelbach: 340B program has changed dramatically with 'little transparency into how patients benefit'
Patient Daily reports | Aug 10, 2026

SoCal Breathe Free warns persistent sinus symptoms may signal chronic inflammation
+ Pharmaceuticals
Patient Daily | Aug 10, 2026

Definium and Compass Pathways advance psychedelic drug candidates toward key milestones